Annexin derivatives suitable for pretargeting in therapy and diagnosis
AssigneeMosaMedix B.V.
InventorsChristiaan Peter Maria Reutelingsperger, Peter Moonen, Ad Vermaire
Life of this patent
Estimating the term…
Loading patent…
AssigneeMosaMedix B.V.
InventorsChristiaan Peter Maria Reutelingsperger, Peter Moonen, Ad Vermaire
Estimating the term…
The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept of pretargeting and include the administration of complexes comprising a recognizable compound A coupled to annexins, and the administration of complexes comprising of pharmaceutical or diagnostic compounds coupled to a compound B recognizing and binding to compound A to subjects. The compositions include annexins, annexin variants, that are not internalized by the target cells, derivatives thereof, and complexes thereof.
An annexin variant, comprising annexin,
An annexin variant wherein the annexin comprises SEQ ID NO:1 for annexin A5 or the corresponding sequences for other annexins, wherein one or more amino acids at positions 16-29, 59-74, 88-102, 135-145, 156-169, 202-231, 259-266 and 305-317, or the corresponding sequences for other annexins, are replaced by other amino acids, and wherein one or amino acids at positions 1-19, 24, 28, 46-64, 86-89, 118-135, 149-150, 157-170, 203-219, 245-248 and 280-294 has been replaced by a cysteine residue.
A method for detecting the presence or absence of cells or cell particles expressing phospholipids comprising:
15-16. (canceled)
Dependencies are inferred from the claim text.